Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 2025
The search for novel and clinically relevant FAAH inhibitors starts with newly disclosed chemical entities. However, reducing translation gaps also requires advances in identifying key biomarkers and developing relevant animal models that mimic target diseases. Additionally, disclosing of innovative chemical templates, including those for allosteric modulation of FAAH, and the identification of suitable and innovative multitarget directed ligands will likely establish FAAH inhibitors as a validated therapeutic option for several diseases.
Authors
- Valentina Onnis (ORCID: https://orcid.org/0000-0002-2438-725X)
- Laura Landolfi
- Federica Moraca (ORCID: https://orcid.org/0000-0002-1077-1971)
- Bruno Catalanotti (ORCID: https://orcid.org/0000-0002-7532-6959)
- Margherita Brindisi (ORCID: https://orcid.org/0000-0001-9119-3773)
Institutions
- University of Cagliari (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Expert Opinion on Therapeutic Patents
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1080/13543776.2026.2619515
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00